Urinary 15-F2t-isoprostane, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan.

To evaluate the role of oxidative stress and aflatoxin exposure on risk of hepatocellular carcinoma (HCC), a case-control study nested within a large community-based cohort was conducted in Taiwan. Baseline urine samples, collected from a total of 74 incident HCC cases and 290 matched controls, were used to determine by enzyme-linked immunosorbent assays the level of urinary 15-F(2t)-isoprostane (15-F(2t)-IsoP), a biomarker of lipid peroxidation. These samples had been previously analyzed for urinary aflatoxin B(1) (AFB(1)) metabolites and 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG). Pearson partial correlation coefficient analysis showed that urinary AFB(1) metabolites and 8-oxodG were significantly associated with the level of urinary 15-F(2t)-IsoP. After adjustment for potential confounding factors in a conditional logistic regression model, urinary 15-F(2t)-IsoP was significantly associated with risk of HCC [above versus below the mean odds ratio (OR) = 2.53, 95% confidence interval (CI) = 1.30-4.93]. Moreover, when compared with subjects in the lowest tertile of 15-F(2t)-IsoP, there was a trend of increasing risk of HCC (P(trend) = 0.0008), with adjusted ORs (95% CIs) of 3.87 (1.32-11.38) and 6.27 (2.17-18.13) for the second and third tertile, respectively. In addition, the combination of urinary 15-F(2t)-IsoP above the mean and chronic hepatitis B virus (HBV) infection resulted in an OR of 19.01 (95% CI = 6.67-54.17) compared with those with low urinary 15-F(2t)-IsoP and without HBV infection. These results suggest that elevated levels of urinary 15-F(2t)-IsoP may be related to increasing level of aflatoxin exposure and are associated with an increased risk of HCC.

[1]  W. Tsai,et al.  Urinary 8-oxodeoxyguanosine, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. , 2006, Carcinogenesis.

[2]  C. Bréchot,et al.  Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis , 2006, Oncogene.

[3]  A. Neugut,et al.  Relationship between Urinary 15-F2t-Isoprostane and 8-Oxodeoxyguanosine Levels and Breast Cancer Risk , 2006, Cancer Epidemiology Biomarkers & Prevention.

[4]  M. Evans,et al.  DNA repair is responsible for the presence of oxidatively damaged DNA lesions in urine. , 2005, Mutation research.

[5]  J. Klaunig,et al.  The role of oxidative stress in carcinogenesis. , 2004, Annual review of pharmacology and toxicology.

[6]  J. Morrow,et al.  The isoprostanes: unique products of arachidonic acid oxidation-a review. , 2003, Current medicinal chemistry.

[7]  C. Wild,et al.  The toxicology of aflatoxins as a basis for public health decisions. , 2002, Mutagenesis.

[8]  J. Morrow,et al.  Factors associated with oxidative stress in human populations. , 2002, American journal of epidemiology.

[9]  A. Srivastava,et al.  Long term effect of aflatoxin B1 on lipid peroxidation in rat liver and kidney: effect of picroliv and silymarin , 2001, Phytotherapy research : PTR.

[10]  J. Morrow,et al.  Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. , 2000, Free radical biology & medicine.

[11]  S. Métairon,et al.  Urinary isoprostane excretion is not confounded by the lipid content of the diet , 1999, FEBS letters.

[12]  G. FitzGerald,et al.  Alcohol-induced generation of lipid peroxidation products in humans. , 1999, The Journal of clinical investigation.

[13]  S. Basu,et al.  F2-isoprostane excretion rate and diurnal variation in human urine. , 1999, Prostaglandins, leukotrienes, and essential fatty acids.

[14]  M. F. Souza,et al.  Inhibition by the Bioflavonoid Ternatin of Aflatoxin B1‐induced Lipid Peroxidation in Rat Liver , 1999, The Journal of pharmacy and pharmacology.

[15]  S. Basu,et al.  Metabolism of 8‐iso‐prostaglandin F2α , 1998 .

[16]  Chien-Jen Chen,et al.  Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan , 1996, International journal of cancer.

[17]  G. FitzGerald,et al.  Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. , 1995, The Journal of pharmacology and experimental therapeutics.

[18]  J. Morrow,et al.  Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. , 1995, The New England journal of medicine.

[19]  C. Ong,et al.  Aflatoxin B1-induced 8-hydroxydeoxyguanosine formation in rat hepatic DNA. , 1995, Carcinogenesis.

[20]  S. Hirohashi,et al.  Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. , 1994, Cancer research.

[21]  J. Morrow,et al.  Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Chien-Jen Chen,et al.  Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma , 1991, Hepatology.

[23]  J. Morrow,et al.  A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Palmiter,et al.  Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice , 1989, Cell.

[25]  A. Neugut,et al.  Relationship between Urinary 15F 2 t-Isoprostane and 8-Oxodeoxyguanosine Levels and Breast Cancer Risk , 2006 .

[26]  S. Basu Metabolism of 8-iso-prostaglandin F2alpha. , 1998, FEBS letters.

[27]  Y. Shen,et al.  Detection of elevated reactive oxygen species level in cultured rat hepatocytes treated with aflatoxin B1. , 1996, Free radical biology & medicine.

[28]  B. Henderson,et al.  A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[29]  J. Morrow,et al.  Quantification of noncyclooxygenase derived prostanoids as a marker of oxidative stress. , 1991, Free radical biology & medicine.